Skip to main content

Advertisement

Table 2 Parasitological efficacy of SP among women enrolled in Burkina-Faso and Mali

From: Parasite clearance following treatment with sulphadoxine-pyrimethamine for intermittent preventive treatment in Burkina-Faso and Mali: 42-day in vivo follow-up study

Characteristics Burkina-Faso Mali All
N=312 N =268 N =580
PCR Days Non- adjusted Adjusted Non- adjusted Adjusted Non- adjusted Adjusted
Day 7:       
Number at risk 307 307 265 265 572 572
Failures, n (%)       
ETF 0 0 0 0 0 0
LCF 0 0 0 0 0 0
LPF 2 (0.5) 1 (0.3) 1 (0.4) 1 (0.4) 3 (0.5) 2 (0.3)
ACPR n (%) 305 (99.5) 306 (99.7 264 (99.6) 264 (99.6) 569 (99.5) 570 (99.7)
Day 14:       
Number at risk 306 306 260 260 566 566
Failures n (%)       
ETF 0 0 0 0 0 0
LCF 0 0 0 0 0 0
LPF 3 (1.0) 2 (0.7) 1 (0.4) 1 (0.4) 4 (0.7) 3 (0.5)
ACPR n (%) 303 (99.0) 304 (99.3 259 (99.6) 259 (99.6 562 (99.3) 563 (99.5)
Day 21:       
Number at risk 300 300 259 259 559 559
Failures n (%)       
ETF 0 0 0 0 0 0
LCF 0 0 0 0 0 0
LPF 3 (1.0) 2 (0.7) 1 (0.4) 1 (0.4) 4 (0.7) 3 (0.5)
ACPR n (%) 297 (99.0) 298 (99.3) 258 (99.6) 258 (99.6) 542 (99.5) 556 (99.5)
Day 28:       
Number at risk 297 297 259 259 556 556
Failures n (%)       
ETF 0 0 0 0 0 0
LCF 0 0 0 0 0 0
LPF 7 (2.4) 3 (1.0) 2 (0.8) 2 (0.8) 9 (1.6) 5 (0.9)
ACPR n (%) 290 (97.6) 294 (99.0) 257 (99.2) 257 (99.2) 547 (98.4) 551 (99.1)
Day 35:       
Number at risk 295 294a 253 254 548 547a
Failures n (%)       
ETF 0 0 0 0 0 0
LCF 0 0 0 0 0  
LPF 14 (4.8) 4 (1.4) 2 (0.8) 2 (0.8) 16 (2.9) 6 (1.1)
ACPR n (%) 281 (95.2) 290 (98.6) 251 (99.2) 252 (99.2) 532 (97.1) 541 (98.9)
Day 42:       
Number at risk 293 292a 253 251a,b 546 544c
Failures n (%)       
ETF 0 0 0 0 0 0
LCF 0 0 0 0 0 0
LPF 19 (6.5) 4 (1.4) 8 (3.2) 2 (0.8) 27 (4.9) 6 (1.1)
ACPR n (%) 274 (93.5) 288 (98.6) 245 (96.8) 249 (99.2) 519 (95.1) 538 (98.9)
Median (range) time in days 35 (7–43)d 21 (7–35)e 42 (7–42)d 18 (7–29)e 35 (7–43)d 21 (7–35)e
  1. Notes: PCR, Polymerase Chain Reaction; ETF, Early Treatment Failure; LCF, Late Treatment Failure; LPF, Late parasitological Failure; ACPR, Adequate Clinical and Parasitological Response.
  2. aOne PCR inconclusive.
  3. bPCR analysis not conducted for 1 woman with recurrent parasitaemia in Mali.
  4. cPCR inconclusive (1 from Mali, 1 from Burkina) and no PCR analysis available (1 from Mali). These three cases were censored in the survival analysis.
  5. dMedian (range) time to reinfection.
  6. eMedian (range) time to PCR-adjusted failure.